Advanced search
1 file | 3.55 MB Add to list

Inhaled GM-CSF administered during ongoing pneumovirus infection alters myeloid and CD8 T cell immunity without affecting disease outcome

Nincy Debeuf (UGent) , Julie Deckers (UGent) , Sahine Lameire (UGent) , Cedric Bosteels (UGent) , Hamida Hammad (UGent) and Bart Lambrecht (UGent)
Author
Organization
Project
Abstract
Granulocyte-macrophage colony stimulating factor (GM-CSF) is a pleiotropic cytokine, able to promote both myelopoiesis and activation of immune cells. Particularly in the lung, GM-CSF plays an important homeostatic role in the development and maintenance of alveolar macrophages, and is therefore considered to play a role in respiratory virus infections such as influenza and SARS-CoV-2, although the benefits of GM-CSF treatment in clinical studies remain inconclusive. To address this, we tested inhaled GM-CSF treatment in the Pneumonia Virus of Mice (PVM) mouse model. Our findings show that local GM-CSF therapy during PVM disease increased local neutrophilia and monocyte-derived cell influx, but diminished CD8+ T cells responses. Despite this, the observed effects on T cells and myeloid cells did not result in an altered clinical outcome during PVM infection. We conclude that inhaled GM-CSF therapy cannot be considered as a universal protective therapy in respiratory virus infections.
Keywords
GM-CSF, pneumonia virus of mice, viral infection, CD8 T cells, inhalation therapy, SUPPRESSOR-CELLS, EXPRESSION, VIRUS, MACROPHAGES

Downloads

  • 5230 24Debeuf.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 3.55 MB

Citation

Please use this url to cite or link to this publication:

MLA
Debeuf, Nincy, et al. “Inhaled GM-CSF Administered during Ongoing Pneumovirus Infection Alters Myeloid and CD8 T Cell Immunity without Affecting Disease Outcome.” FRONTIERS IN IMMUNOLOGY, vol. 15, 2024, doi:10.3389/fimmu.2024.1439789.
APA
Debeuf, N., Deckers, J., Lameire, S., Bosteels, C., Hammad, H., & Lambrecht, B. (2024). Inhaled GM-CSF administered during ongoing pneumovirus infection alters myeloid and CD8 T cell immunity without affecting disease outcome. FRONTIERS IN IMMUNOLOGY, 15. https://doi.org/10.3389/fimmu.2024.1439789
Chicago author-date
Debeuf, Nincy, Julie Deckers, Sahine Lameire, Cedric Bosteels, Hamida Hammad, and Bart Lambrecht. 2024. “Inhaled GM-CSF Administered during Ongoing Pneumovirus Infection Alters Myeloid and CD8 T Cell Immunity without Affecting Disease Outcome.” FRONTIERS IN IMMUNOLOGY 15. https://doi.org/10.3389/fimmu.2024.1439789.
Chicago author-date (all authors)
Debeuf, Nincy, Julie Deckers, Sahine Lameire, Cedric Bosteels, Hamida Hammad, and Bart Lambrecht. 2024. “Inhaled GM-CSF Administered during Ongoing Pneumovirus Infection Alters Myeloid and CD8 T Cell Immunity without Affecting Disease Outcome.” FRONTIERS IN IMMUNOLOGY 15. doi:10.3389/fimmu.2024.1439789.
Vancouver
1.
Debeuf N, Deckers J, Lameire S, Bosteels C, Hammad H, Lambrecht B. Inhaled GM-CSF administered during ongoing pneumovirus infection alters myeloid and CD8 T cell immunity without affecting disease outcome. FRONTIERS IN IMMUNOLOGY. 2024;15.
IEEE
[1]
N. Debeuf, J. Deckers, S. Lameire, C. Bosteels, H. Hammad, and B. Lambrecht, “Inhaled GM-CSF administered during ongoing pneumovirus infection alters myeloid and CD8 T cell immunity without affecting disease outcome,” FRONTIERS IN IMMUNOLOGY, vol. 15, 2024.
@article{01JCZQ0AM06YJNV3RHYQRM4WD3,
  abstract     = {{Granulocyte-macrophage colony stimulating factor (GM-CSF) is a pleiotropic cytokine, able to promote both myelopoiesis and activation of immune cells. Particularly in the lung, GM-CSF plays an important homeostatic role in the development and maintenance of alveolar macrophages, and is therefore considered to play a role in respiratory virus infections such as influenza and SARS-CoV-2, although the benefits of GM-CSF treatment in clinical studies remain inconclusive. To address this, we tested inhaled GM-CSF treatment in the Pneumonia Virus of Mice (PVM) mouse model. Our findings show that local GM-CSF therapy during PVM disease increased local neutrophilia and monocyte-derived cell influx, but diminished CD8+ T cells responses. Despite this, the observed effects on T cells and myeloid cells did not result in an altered clinical outcome during PVM infection. We conclude that inhaled GM-CSF therapy cannot be considered as a universal protective therapy in respiratory virus infections.}},
  articleno    = {{1439789}},
  author       = {{Debeuf, Nincy and Deckers, Julie and Lameire, Sahine and Bosteels, Cedric and Hammad, Hamida and Lambrecht, Bart}},
  issn         = {{1664-3224}},
  journal      = {{FRONTIERS IN IMMUNOLOGY}},
  keywords     = {{GM-CSF,pneumonia virus of mice,viral infection,CD8 T cells,inhalation therapy,SUPPRESSOR-CELLS,EXPRESSION,VIRUS,MACROPHAGES}},
  language     = {{eng}},
  pages        = {{9}},
  title        = {{Inhaled GM-CSF administered during ongoing pneumovirus infection alters myeloid and CD8 T cell immunity without affecting disease outcome}},
  url          = {{http://doi.org/10.3389/fimmu.2024.1439789}},
  volume       = {{15}},
  year         = {{2024}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: